Peptidase activities in rats treated chronically with Nω-nitro-L-arginine methyl ester (L-NAME)

[1]  A. Agarwal,et al.  The story so far: Molecular regulation of the heme oxygenase-1 gene in renal injury. , 2004, American journal of physiology. Renal physiology.

[2]  W. Simmons,et al.  Proline specific endo- and exopeptidases , 1980, Molecular and Cellular Biochemistry.

[3]  Carol Cass,et al.  Nitric Oxide and Cyclic GMP Increase the Expression of Matrix Metalloproteinase-9 in Vascular Smooth Muscle , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[5]  Michael,et al.  Metalloendopeptidases EC 3.4.24.15/16 regulate bradykinin activity in the cerebral microvasculature. , 2003, American journal of physiology. Heart and circulatory physiology.

[6]  A. H. Jan Danser,et al.  Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? , 2003, The international journal of biochemistry & cell biology.

[7]  M. Norman,et al.  Endopeptidases 3.4.24.15 and 24.16 in endothelial cells: potential role in vasoactive peptide metabolism. , 2003, American journal of physiology. Heart and circulatory physiology.

[8]  J. Michel,et al.  The Serpin Protease-Nexin 1 Is Present in Rat Aortic Smooth Muscle Cells and Is Upregulated in l-NAME Hypertensive Rats , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Lijun Li,et al.  Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling. , 2003, Advances in experimental medicine and biology.

[10]  B. McDermott,et al.  Induction of Hypertrophic Responsiveness of Cardiomyocytes to Neuropeptide Y in Response to Pressure Overload , 2002, Journal of Pharmacology and Experimental Therapeutics.

[11]  A Ian Smith,et al.  Soluble metalloendopeptidases and neuroendocrine signaling. , 2002, Endocrine reviews.

[12]  J. Rouleau,et al.  Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? , 2001, Circulation.

[13]  R. V. Sharma,et al.  Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. , 2001, Journal of applied physiology.

[14]  M. Hori,et al.  Differential Subcellular Actions of ACE Inhibitors and AT1 Receptor Antagonists on Cardiac Remodeling Induced by Chronic Inhibition of NO Synthesis in Rats , 2001, Hypertension.

[15]  J. Pfeilschifter,et al.  Regulation of gene expression by nitric oxide , 2001, Pflügers Archiv.

[16]  M. Hayashi,et al.  Free ATP inhibits thimet oligopeptidase (EC 3.4.24.15) activity, induces autophosphorylation in vitro, and controls oligopeptide degradation in macrophage. , 2001, European journal of biochemistry.

[17]  H. Heitsch,et al.  Angiotensin-(1-7)–Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells , 2001, Hypertension.

[18]  J. Martignetti,et al.  The Neuropeptide Processing Enzyme EC 3.4.24.15 Is Modulated by Protein Kinase A Phosphorylation* , 2000, The Journal of Biological Chemistry.

[19]  D. Kang,et al.  Effects of nitric oxide synthesis inhibition on the atrial natriuretic peptide system. , 2000, Pharmacological research.

[20]  W. Gonzalez,et al.  Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. , 2000, Hypertension.

[21]  R. Evans,et al.  A novel stable inhibitor of endopeptidases EC 3.4.24.15 and 3.4.24.16 potentiates bradykinin-induced hypotension. , 2000, Hypertension.

[22]  A. Takeshita,et al.  Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. , 2000, Circulation.

[23]  G. Abbenante,et al.  Development and characterization of novel potent and stable inhibitors of endopeptidase EC 3.4.24.15. , 2000, The Biochemical journal.

[24]  O. Pechanova,et al.  Chronic disturbances in NO production results in histochemical and subcellular alterations of the rat heart. , 2000, Physiological research.

[25]  J. Pfeilschifter,et al.  Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. , 2000, Kidney international.

[26]  James L. Roberts,et al.  Differential subcellular distribution of neurolysin (EC 3.4.24.16) and thimet oligopeptidase (EC 3.4.24.15) in the rat brain , 1999, Brain Research.

[27]  A. Takeshita,et al.  Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. , 1999, Hypertension.

[28]  P. Kovanen,et al.  Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. , 1999, Circulation.

[29]  C. Durinx,et al.  The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. , 1999, Current medicinal chemistry.

[30]  C. Baylis,et al.  Chronic nitric oxide inhibition model six years on. , 1998, Hypertension.

[31]  Ferrario Cm.  Angiotension-(1-7) and antihypertensive mechanisms. , 1998 .

[32]  A. Takeshita,et al.  Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. , 1998, Circulation research.

[33]  J. Roberts,et al.  Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 3.4.24.16 family: comparison with the related recombinant endopeptidase 3.4.24.15. , 1998, Biochemical and biophysical research communications.

[34]  D. Ganten,et al.  Converting enzyme determines plasma clearance of angiotensin-(1-7). , 1998, Hypertension.

[35]  A. Takeshita,et al.  Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. , 1998, Hypertension.

[36]  M. Paul,et al.  Modulation of angiotensin‐converting enzyme by nitric oxide , 1998, British journal of pharmacology.

[37]  A. Takeshita,et al.  Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. , 1997, Hypertension.

[38]  F. Graeff,et al.  Acute inhibition of nitric oxide synthesis induces anxiolysis in the plus maze test. , 1997, European journal of pharmacology.

[39]  A. Takeshita,et al.  Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. , 1997, The Journal of clinical investigation.

[40]  R. Ardaillou.  Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. , 1997, Current opinion in nephrology and hypertension.

[41]  R. Mentlein,et al.  Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells , 1996, Peptides.

[42]  K. Metze,et al.  Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. , 1995, European journal of pharmacology.

[43]  X. J. Zhou,et al.  Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. , 1994, The American journal of physiology.

[44]  M. Fournié-Zaluski,et al.  Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. , 1993, Pharmacological reviews.

[45]  F. Naider,et al.  Proline-dependent structural and biological properties of peptides and proteins. , 1993, Critical reviews in biochemistry and molecular biology.

[46]  C. Ferrario,et al.  A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. , 1993, Life sciences.

[47]  R. Skidgel.  Bradykinin‐Degrading Enzymes: Structure, Function, Distribution, and Potential Roles in Cardiovascular Pharmacology , 1992, Journal of cardiovascular pharmacology.

[48]  R. Zatz,et al.  Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. , 1992, Hypertension.

[49]  M. Montrose,et al.  Assay of apical membrane enzymes based on fluorogenic substrates. , 1992, Analytical biochemistry.

[50]  T. Aoyagi,et al.  Leuhistin, a new inhibitor of aminopeptidase M, produced by Bacillus laterosporus BMI156-14F1. I. Taxonomy, production, isolation, physico-chemical properties and biological activities. , 1991, The Journal of antibiotics.

[51]  A. Barrett,et al.  A distinct thimet peptidase from rat liver mitochondria , 1990, FEBS letters.

[52]  R. Zatz.  A low cost tail-cuff method for the estimation of mean arterial pressure in conscious rats. , 1990, Laboratory animal science.

[53]  R. Skidgel,et al.  Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1 , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  F. Palmieri,et al.  Metabolism of vasoactive peptides by vascular endothelium and smooth muscle aminopeptidase M. , 1989, Biochemical pharmacology.

[55]  J. Schwartz,et al.  Distribution of enkephalinase (membrane metalloendopeptidase, E.C. 3.4.24.11) in rat organs. Detection using a monoclonal antibody. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[56]  J. Schwartz,et al.  Major localization of aminopeptidase M in rat brain microvessels , 1987, Neuroscience.

[57]  R. Busse,et al.  Stimulation of Soluble Guanylate Cyclase by an Acetylcholine‐Induced Endothelium‐Derived Factor from Rabbit and Canine Arteries , 1986, Circulation research.

[58]  F. Palmieri,et al.  Vascular, plasma membrane aminopeptidase M. Metabolism of vasoactive peptides. , 1985, Biochemical pharmacology.

[59]  B. Roques,et al.  A highly sensitive fluorometric assay for "enkephalinase," a neutral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins. , 1984, Analytical biochemistry.

[60]  T Takeuchi,et al.  Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. , 1984, The Journal of antibiotics.

[61]  T. Kato,et al.  Purification and properties of rat brain dipeptidyl aminopeptidase. , 1983, Journal of biochemistry.

[62]  G. Püschel,et al.  Isolation and characterization of dipeptidyl peptidase IV from human placenta. , 1982, European journal of biochemistry.

[63]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H Umezawa,et al.  Structures and activities of protease inhibitors of microbial origin. , 1976, Methods in enzymology.

[65]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[66]  D. Holberton.  Microtubules in the Cytoplasm of an Amoeba , 1969, Nature.

[67]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.